Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NuVasive IPO: Minimally Invasive Spine Firm Offers Up To $92 Mil. In Stock

This article was originally published in The Gray Sheet

Executive Summary

NuVasive plans to use proceeds from its initial public offering to develop injectable disc nucleus replacement materials and total lumbar disc products

You may also be interested in...



NuVasive Prepares Cervical Disc IDE Filing; Fusion Plate To Launch In July

NuVasive intends to file an IDE application for a minimally-invasive cervical total artificial disc replacement within the next two weeks

NuVasive Prepares Cervical Disc IDE Filing; Fusion Plate To Launch In July

NuVasive intends to file an IDE application for a minimally-invasive cervical total artificial disc replacement within the next two weeks

NuVasive Facility Expansion Triples Capacity; Stock Up 24% In January

Spinal surgery system maker NuVasive's recently expanded production, training and warehousing capacity is spurring investor optimism that drove a 24.3% stock price increase in January to $12.7

Related Content

UsernamePublicRestriction

Register

MT019912

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel